替吉奥联合伊立替康治疗晚期结肠癌的临床研究

目的:比较替吉奥联合伊立替康与替吉奥单药治疗晚期结肠癌的临床疗效。方法:选取2011年3月~2012年3月我院收治的晚期结肠癌患者90例,按照随机数字表法将患者分为研究组和对照组,每组45例,研究组给予替吉奥联合伊立替康,对照组给予替吉奥单药治疗,比较两组近期疗效、远期疗效和不良反应。结果:研究组的总有效率51.1%(23/45)显著高于对照组的26.7%(12/45),两组比较差异具有统计学意义(X2=13.281,P=0.017);研究组中位进展时间和中位生存时间均显著长于对照组,两组比较差异具有统计学意义(t=9.029,10.412,P=0.021,0.019);两组中性粒细胞减少和腹泻比较差异具有统计学意义(X2=11.517,12.041;P=0.023,0.019)。结论:替吉奥联合伊立替康治疗晚期结肠癌较单用替吉奥具有更好的治疗效果,值得临床推广应用。

The Clinical Research of Gio Combined with Irinotecan in Treatment ofAdvanced Colorectal Cancer

Objective:To compare the clinical efficacy of Gio combined with irinotecan and monotherapy of Gio in treatment ofadvanced colorectal cancer.Methods:90 cases of advanced colorectal cancer were selected fromour hospital from March 2011 to March2012, and they were divided into the study group and the control group according to the random number table, with 45 cases in eachgroup. The study group were treated with Gio combined with irinotecan, and the control group were treated with Gio alone, theshort-termeffect, long-term efficacy and adverse reactions of two groups were compared.Results:The total efficiency of the study groupwas 51.1% (23/45), significantly higher than 26.7% (12/45) of the control group, and the difference was statistically significant (X2=13.281, P=0.017); The median progression time and median survival time of the study group were significantly longer than those of thecontrol group, the differences were statistically significant (t=9.029, 10.412, P=0.021, 0.019); Incidence of Neutropenia and diarrhea ofthe two groups showed statistically significant difference(X2=11.517, 12.041; P=0.023, 0.019).Conclusion:Gio combined with irinotecanhad better efficacy in treatment of advanced colorectal cancer when compared with mono-therapy of Gio. It is worthy of clinicalapplication.